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Background: Although the prevalence of esophageal cancer increases in elderly patients,
its clinical history and outcome after treatment remain poorly described.
Methods: Between January 2001 and December 2011, 58 patients (pts) older than 75 years
received 3D-conformal radiotherapy (mean dose 51 Gy) in two French cancer centers. 47/58
(82%) patients received concomitant chemotherapy (with CDDP and/or FU regimens) and
8 patients underwent surgery after primary radiochemotherapy (RCT).
Results: Median age was 77.9 years and the performance status (PS) was 0 or 1 in
89%. Tumors were mainly adenocarcinoma of lower esophagus or gastroesophageal
junction (n=51, 89%), T3T4 (n=54, 95%), and N1 (n=44, 77%). The mean follow-up
was 21.9 months. In the overall population, the median progression-free survival was
9.6 months and median overall survival (OS) was 14.5 months. Using univariate analysis, OS
was significantly associated with age (p=0.048), PS (p<0.001), and surgery (p=0.035).
35 (60.3%) and 18 patients (31%) experienced grade 1–2 or 3–4 toxicity, respectively
(CTCAE v4.0).
Conclusion: Radiochemotherapy in elderly patients is a feasible treatment and its outcome
is close to younger patient’s outcome published in the literature. Surgical resection, after
comprehensive geriatric assessment, should be recommended as the standard treatment
for adenocarcinoma of lower esophagus or gastroesophageal junction in elderly patients
with good PS and low co-morbidity profile, as it is in younger patients.
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INTRODUCTION
Esophageal cancer (OC) is the eighth most common cancer world-
wide, with 481,000 new cases (3.8% of the total) estimated in
2008, and the sixth most common cause of death from cancer
with 406,000 deaths (5.4% of the total) (1). In most western
countries, squamous cell carcinoma (SCC) incidence rates con-
tinue to decrease while incidence of adenocarcinoma is rocketing
up (2). Furthermore, OC has a very poor survival (overall ratio
of mortality to incidence of 0.88) (3). The incidence of OC
in elderly patients has rapidly increased in the Western coun-
tries over the past 25 years, with a specific mortality increasing
with age (4).
Recently, the field of OC management improved in several
ways: (i) demonstration that the dose of 50 Gy seemed to be
the better option (5), (ii) evidence from meta-analysis in favor
of neoadjuvant chemotherapy or chemoradiotherapy (6), and
(iii) the demonstration of the good efficacy – safety balance in
favor of FOLFOX regimen (5-FU and Oxaliplatin) when com-
pared with usual 5-FU-CDDP (Cisplatin) (7). Nevertheless, none
of these trials presented sub-group data analysis focused on
elderly patients. Furthermore, patients older than 75 years are
often excluded from clinical trials (8, 9) and there is a lack in
prospective studies in this specific population. That leads to the
fact that little is known about the optimal treatment of this
population.
A retrospective cohort study of 3500 patients (10) reported
that older people are less referred to cancer specialist and thus,
have less intensive treatment, which may partially explain the poor
results of OC management among elderly patients. Particularly,
a larger number of older patients eligible for esophageal resec-
tion are contra-indicated with regards to the aggressiveness of the
surgery. For non-resectable OC, the strategy generally adopted
is radiotherapy with or without concomitant chemotherapy. In
elderly patients however, the dose of radiation and the protocols
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of chemotherapy is non-consensual (for example, Servagi-Vernat
et al. used CDDP alone, and Anderson et al. used 5-FU and
mitomycin C in association) (11, 12).
The aim of this retrospective multicentric study was to analyze
the management and the outcome of 58 elderly patients treated
by radiotherapy with or without concomitant chemotherapy and
with or without surgery for an OC in two French centers, between
January 2001 and December 2011.
MATERIALS AND METHODS
ELIGIBILITY CRITERIA
Inclusion criteria were as follows: histologically proven SCC or
adenocarcinoma of the esophagus or gastroesophageal junction,
local or loco-regional disease at diagnosis, age ≥75 years, treat-
ment by radiotherapy (exclusive or not) between January 2001
and December 2011 in two French centers. No selection was made
regarding performance status (PS), co-morbidity, or biological
characteristics. Comorbidities were estimated using the Charlson
score adjusted on age (13), which combines a score for 19 disease
co-morbidity categories (from 1 to 6 based on the relative risk of
1-year mortality) and the patient’s age (one point per decade from
50 to 70 years old).
TUMORAL STAGING AND EVALUATION OF THE RESPONSE
All patients underwent an initial gastrointestinal fibroscopy and
ultrasonography (OGUS) with biopsies and a thoraco-abdominal
CT-scan. Tumors were staged using CT-scan and OGUS, accord-
ing to the seventh edition of the Union for International Cancer
Control and the American Joint Committee on Cancer (14). The
toxicity was evaluated by a weekly clinical examination, and with a
biological evaluation before every cycle of chemotherapy. All tox-
icities were recorded using the Common Terminology Criteria for
Adverse Events v4.0 (CTCAE). The tumor response was evaluated
by an OGUS and a CT-scan realized 1 and 2 months after the end
of treatment, every 3 months during the first year, and then every
6 months.
TREATMENTS
Every treatment was debated during a tumor board including at
least a surgeon, a radiation oncologist, a medical oncologist, and
a radiologist. Because of the retrospective approach of this study,
an onco-geriatric evaluation was not systematically realized.
Radiation therapy was delivered using 3D-conformal RT. Gross
Tumor Volume (GTV) was determined with every useful informa-
tion (clinical examination, CT-scan, and endoscopy) and included
the primary tumor site and regional macroscopically involved
lymph nodes. For patients eligible for a surgical resection, the
Planning Target Volume (PTV) was defined by a proximal and
distal margin of 5 cm and radial margin of 1 cm around the GTV.
In case of stomach’s extension, the upper third part of the stom-
ach was added to the PTV. For patients non-eligible for surgery, a
radiation boost was often delivered on the GTV plus 2 cm margin
in longitudinal extension, and 1 cm margin in sagittal and axial
extension.
Concomitant chemotherapy was performed whenever possible,
as decided by the multidisciplinary consultation meeting. Systemic
treatment regimen was adapted to patient’s characteristics (PS,
co-morbidity, and biological results) and was based on platinum
derivatives and/or 5 FU. Surgery was performed in accordance
with the tumor board decision, after a surgical and a pre-anesthesia
evaluation, and after a neoadjuvant RCT of 45 Gy with fractions
of 1.8 Gy/day, 5 days a week. The choice of transthoracic or tran-
shiatal esophagectomy was dictated by the location of the tumor
and the preference of the surgeon.
STATISTICAL ANALYSIS
Overall survival (OS) was calculated from the date of initial pos-
itive biopsy until the date of death or the date of last follow-up.
Progression-Free Survival (PFS) was estimated from the date of
endoscopy to the date of progression (loco-regional or metastatic)
or the date of death or last follow-up. Loco-regional progressions
were proven histologically, whereas metastatic progressions were
diagnosed on CT-scan. OS and PFS curves were constructed using
the Kaplan–Meier method (15). Prognostic factors for OS and
PFS were obtained using the log-rank test and statistical signif-
icance was defined with a p-value <0.05. All prognostic factors
with a p< 0.2 were included for a multivariate analysis using a
Cox regression. Surgical and non-surgical populations were com-
pared using a Pearson’s χ2 test. Analyses were performed with
SPSS v16.0.
RESULTS
PATIENT AND TUMOR CHARACTERISTICS
Fifty-eight patients were enrolled in this study, from two French
Cancer Centers: Institut Paoli Calmettes, Marseille (n= 33) and
Centre de Radiothérapie St Louis, Toulon (n= 25). The patients
>75 years represent 9% of the total of patients treated by RT for
an OC in these centers. Characteristics of patients and tumors
are described in Table 1. Median age was 77.8 years (range of 75–
87 years). Most of the patients had a good PS: PS 0 (n= 12, 20%) or
PS 1 (n= 40, 69%). Concerning co-morbidity, 37 patients (64%)
had a Charlson score <5 and 21 (36%) had a Charlson score ≥5,
with a median Charlson score of 4 (3–7).
Among all the 58 histologically proven carcinoma, 43 were
adenocarcinoma (74%). Tumors involved mostly the gastroe-
sophageal junction (GOJ) (n= 31) and the lower third of the
esophagus (n= 20). A large majority of the patients presented
a locally advanced tumor T3N0-1 (n= 41) or T4 N0-1 (n= 5).
TREATMENT CHARACTERISTICS
The main characteristics of the delivered treatments are described
in Table 2. All patients underwent radiotherapy, with a mean deliv-
ered dose of 50.9 Gy (27–72 Gy). The median and mean numbers
of treatment days were respectively 43 and 46 days (22–117).
Forty-seven patients received concomitant chemotherapy: 20
had weekly Carboplatin (AUC2), 10 had Herskovic regimen (4
CDDP/5 FU chemotherapy courses with 5 FU 1000 mg/m2 at days
1–5 and CDDP at 75 mg/m2 at day 1), 7 had weekly CDDP
(40 or 60 mg/m2), 4 had 5 FU-Carboplatin (every 21 days: 5 FU:
750 mg/m2 at days 1–5; Carboplatin AUC4), 3 had FOLFOX 4, 2
had capecitabine (100 mg/m/m2), and 1 had exclusive 5-FU (dose
unknown).
Exclusive RT (without chemotherapy or surgery) was per-
formed in 11 patients, because of age (n= 3), co-morbidity
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Table 1 | Patient and tumor characteristics.
Variable n=58 (%)
AGE
75–80 42 (72.4)
80–85 13 (22.4)
>85 3 (5.2)
SEX
Male 43 (74.1)
Female 15 (25.8)
WHO PERFORMANCE STATUS
0 12 (20.6)
1 40 (68.9)
2 5 (8.6)
3 1 (1.7)
CHARLSON SCORE ADJUSTED ON AGE
3 17 (29.3)
4 20 (34.4)
5 13 (22.4)
6 5 (8.6)
7 3 (5.2)
LOCALIZATION ESOPHAGUS
Upper one-third 2 (3.4)
Middle one-third 5 (8.6)
Lower one-third 20 (34.5)
GOJ 31 (53.4)
STAGE
TX NX 2 (3.4)
T1N1 1 (1.7)
T2N1 1 (1.7)
T3N0 4 (6.9)
T3N1 37 (63.8)
T3N2 1 (1.7)
T3NX 7 (12.1)
T4N0 1 (1.7)
T4N1 4 (6.9)
HISTOLOGICALTYPE
Adenocarcinoma 43 (74.1)
Squamous cell carcinoma 14 (24.1)
Undifferentiated 1 (1.7)
HISTOLOGICAL DIFFERENTIATION
Well 14 (24.1)
Moderately 13 (22.4)
Poorly 7 (12.1)
Unknown 24 (41.4)
GOJ, gastroesopageal junction.
(n= 2), asthenia (n= 2), patient’s refusal (n= 1), or unknown
reasons (n= 3).
Eight patients underwent esophagectomy, including seven tran-
shiatal surgeries and one transthoracic Lewis Santy procedure. All
the operated patients had GOJ cancer, an age <80 years, a Charl-
son score ≤4, and a good PS (PS 0–1: n= 7; PS 2: n= 1). Three
patients had pathological lymph nodes on the post-operative find-
ings (see Table S1 in Supplementary Material) but none of them
was treated with an adjuvant chemotherapy.
Table 2 |Treatment characteristics.
Variable Total
N° (%)
RADIATIONTHERAPY (N =58)
Dose<50.4 Gy 23 (39.6)
Dose=50.4 Gy 12 (20.6)
Dose>50.4 Gy 23 (39.6)
Mean dose (Gy) 50.9 (±8.4)
CHEMORADIOTHERAPY PROTOCOL (N =47)
Weekly CDDP or Carboplatin 27 (57.4)
5-FU and platinum regimen 17 (36.2)
5-FU alone 3 (6.4)
CDDP, Cisplatine; 5-FU, 5 Fluoro-Uracile.
TREATMENT OUTCOME AND SURVIVAL
The mean follow-up of the population was 21.9 months
(2.1–100.9).
The median PFS of the overall population was 9.6± 3.9 months
(Figure 1A). Using univariate analysis, PS status and age<78 years
(inferior to the median) were the only significant predictive fac-
tors for PFS (p= 0.012 and p= 0.019, respectively). The fol-
lowing factors were not significantly associated with PFS: sex,
Charlson score, surgery, concomitant chemotherapy, and RT dose
(see Table 3). Thirty-four patients relapsed: 17 loco-regionally,
8 with distant metastases, and 9 with both loco-regional and
distant relapse. The 2- and 3-year-cumulative rates of local
recurrence were 36.2 and 41.4%, respectively. The only posi-
tive predictive factor for local control was age: 2-years local
relapse for patients <78 years was 64.0%, vs. 92.6% for patients
≥78 years (p= 0.021). Concerning metastatic recurrence, no
prognostic factors were identified and the preferential localiza-
tions were mainly pleuropulmonar (n= 5), peritoneal (n= 3),
hepatic (n= 2), and cerebral (n= 1), with a few unknown data
(n= 5).
The median overall survival (OS) of the overall population was
14.5± 4.7 months (standard deviation), and 2 and 3 years-overall
survival rates were 25.9 and 15.5%, respectively (Figure 1B).
Using univariate analysis, the OS was positively influenced by
age <78 years (p= 0.048, Figure S1 in Supplementary Material),
a good PS (p< 0.001, Figure S2 in Supplementary Material), and
the realization of surgery (p= 0.035). Details of the univariate
analysis for OS are given in Table 3.
Curative esophagectomy (Figure 2) was associated with a
median OS of 18.3± 9.7 vs. 10.5± 3.5 months for patient without
surgery (p= 0.035).
There was no significant difference in terms of OS in univariate
analysis for sex, Charlson score, histology, degree of differentiation,
and tumor size >50 mm, usTN, pTN, RT dose, and concomitant
chemotherapy. Accordingly with the univariate analysis results,
none of the prognostic factors were significative in multivariate
analysis.
47/58 died within 2 years: 30/47 deaths were due to OC dis-
ease progression, 6/47 due to complications of therapy, and the
remainder to non-cancer (6/47) or unknown causes (5/47).
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FIGURE 1 | Kaplan–Meier methods for elderly patients treated for
esophageal and gastroesophageal cancer. (A) Progression-free survival
curve (B) overall survival curve.
TOLERANCE
During RT or RCT, grade 1–2 and 3–4 side effects occurred in 35
patients (60.3%) and in 18 patients (31%), respectively. The main
hematologic side effects were febrile neutropenia (n= 7, 14.9%),
thrombopenia (grade 3–4: n= 6, 12.8%), and anemia (grade 3–4:
n= 3, 6.4%). The main non-hematologic side effects were dyspha-
gia (grade 3–4,n= 9, 19.1%), nausea (grade 3–4:n= 3, 6.4%), and
asthenia (grade 1–2: n= 6, 12.7% and grade 3–4: n= 1). There
were only a few grade 1–2 mucositis and skin toxicity (n= 4 and
n= 1, respectively). Interruptions of radiation therapy occurred
in 13 patients (22%), temporarily (n= 7) or definitively (n= 6) at
a mean dose of 35.8 Gy (26–40 Gy).
During RCT (n= 47), 18 patients (38.2%) had to be hospi-
talized, mainly for severe malnutrition (n= 7) or febrile neu-
tropenia (n= 7). One toxic death occurred during RCT (asthenia,
dysphagia).
Patients with exclusive RT (n= 11) had no hematologic side
effects but more grade 3–4 asthenia (n= 5) and a comparable
dysphagia (grade 3–4, n= 2, 18.2%) and hospitalization rate
(n= 3, 27.3%). One toxic death occurred during exclusive RT
(asthenia, severe malnutrition).
Surgical complications were described as follows: one gastric
necrosis after gastroplasty, one anastomotic fistula with sub-
cutaneous emphysema (both of them recovered after transfer
in an intensive care unit), one anastomotic stenosis (2 months
after the transthoracic procedure, treated by endoscopic dilata-
tions), and one recurrent paralysis (with a good rehabilitation).
None of the eight patients operated died in the 30 days after
surgery.
DISCUSSION
We present here a large cohort of elderly patients treated with
radiotherapy for an esophageal cancer.
Due to its retrospective nature, our analysis suffers from limi-
tations, including the absence of a consistent onco-geriatric eval-
uation and systematic integration of quality-of-life assessment.
Furthermore, a median follow-up of 21.9 months is rather short
to precisely evaluate overall and/or specific survival, as well as their
prognostic factors. This might explain why some validated prog-
nostic factors do not reach significance in our results (e.g., T stage).
In addition, therapeutic strategies were rather heterogeneous, in
part due to the improvements made over the 10 years inclusion
period. Finally, one could argue that SCC and adenocarcinoma
are different diseases, even though most analysis including ours
did not show any major differences in outcome.
On the other hand, this study concerned a consistent number of
patients treated in only two experimented cancer centers, avoiding
misleading factors such as variations of clinical staging between
physicians. Technical reproducibility was guaranteed by the fact
that the same team performed the endoscopic evaluation in the
two centers.
In comparison with published data, our population is more
homogeneous regarding age, as we chose an inferior limit at
75 years instead of 70 years (11) or 65 years (12). Furthermore,
patients were not selected for PS or co-morbidity, contrary to
the study of Anderson et al. in which only patients with Karnof-
sky Index >70% were included and in the study of Servagi-
Vernat et al. in which 50% of patients were excluded for PS
>2 or Charlson score >4. Consequently, our population can be
considered as representative of routine clinical practice. Finally,
every patient’s case was discussed in a multidisciplinary meeting
with a medical oncologist, a radiation oncologist, and a surgeon.
All the range of treatments, even surgery, could be discussed,
which prevent the risk of undertreatment that is huge in elderly
patients.
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Table 3 | Univariate analysis for overall and progression-free survival in population treated in a curative intent.
Overall survival Progression-free survival (24 months)
N° Survival: N°(%) p-Value Survival: N°(%) p-Value
GENDER
Men 43 12(27.9) 0.65 9(20.9) 0.64
Women 15 3(20.0) 3(20.0)
AGE
<78 years 29 11(37.9) 0.048 10(34.5) 0.019
≥78 years 29 4(13.8) 2(6.9)
WHO PERFORMANCE STATUS
0 12 5(41.7) <0.001 4(33.3) 0.012
1 38 10(26.3) 8(21.0)
2 6 0(0) 0(0)
3 2 0(0) 0(0)
CHARLSON SCORE
3–4 37 9(24.3) 0.80 7(18.9) 0.43
≥5 21 5(23.8) 5(23.8)
LOCALIZATION OF OC
Upper and medium 7 1(14.3) 0.27 1(14.3) 0.49
Low and GOJ 51 14(27.5) 10(19.6)
HISTOLOGY
SCC 14 2(14.3) 0.59 2(14.3) 0.42
Adenocarcinoma 43 13(30.2) 9(20.9)
T
T 0/T 1/T 2 3 3(100) 0.67 1(33.3) 0.78
T 3/T 4 43 11(25.6) 11(25.6)
N
N0 5 2(40.0) 0.57 2(40.0) 0.76
N >0 43 11(25.6) 10(23.2)
SURGERY
Yes 8 4(50.0) 0.035 3(37.5) 0.093
No 50 11(22.0) 9(18.0)
CONCOMITANT CHEMOTHERAPY
Yes 47 12(25.5) 0.31 14(29.8) 0.49
No 11 3(27.3) 3(27.3)
RADIATION DOSE
<50.4 Gy 27 8(29.6) 0.86 4(14.8) 0.93
≥50.4 Gy 31 7(22.6) 6(19.4)
OC, esophageal cancer; GOJ, gastroesophageal junction; SCC, squamous cell carcinoma.
The results we found in terms of OS and PFS are consistent with
those published in the literature, notably in the largest cohort of
109 elderly patients treated with exclusive RCT with a median OS
and PFS of 15.2 and 8.3 months, respectively (16). In another small
prospective study of 22 patients>75 years old treated by exclusive
RCT (50 Gy and weekly cisplatin), the median OS was 15 months
(11). Only a study by a team from Memorial Sloan Kettering
described a better OS (median of 35 months) but with only 22
patients included, who were younger and with fewer comorbidities
compared to our study (12).
Moreover, patient outcomes described here are not so far from
the results published in the literature for younger counterparts. In
the most important clinical trials, including patients below the age
of 75 years old, median OS ranged between 13.0 and 19.3 months
(5, 8, 17). This emphasizes the fact that curative treatments of OC
should not be rejected only on age’s argument.
In our study, the best results in terms of OS were obtained for
patients who underwent neoadjuvant RCT followed by esophagec-
tomy. Coia et al. also found a superiority of esophagectomy in the
2 years survival rate (50.2 vs. 31.2%) in the general population
receiving RT in MSKCC between 1992 and 1994 (18). In a study
by Ruol and colleagues, concerning 62 patients over 80 years old,
esophagectomy was found to be a prognostic factor in OC with
an important difference in OS: 14.6 vs. 5.1 months in resected
and non-resected patients, respectively (19). Despite the fact that
esophagectomy is a major surgical procedure, Markar et al. indi-
cated that there were no significant differences in terms of length
of hospitalization and survival rate for patients over 80 years in
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FIGURE 2 | Overall survival curve using Kaplan–Meier methods for
elderly patients treated for esophageal and gastroesophageal cancer,
with surgery (dotted line) or without (full line).
comparison to younger counterparts (20). In our study, surgery
was associated with local complications (anastomosis stenosis,
necrosis of gastroplasty, and fistula) but without perioperative
death. Along this line, previous results showed that a lower 30-
day mortality rate after esophagectomy is obtained when surgery
is realized in a specialized center (21). Together with previous evi-
dence (22), our results suggest that surgical resection is feasible
even in elderly patients, which was not predictable, because age
still appears as a risk factor in certain predictive scores (23).
Concerning RCT tolerance, our results are close to the data
of the literature as Tougeron and Anderson presented 22 and
36% of grade 3–4 toxicity, respectively. In elderly patients with
5 FU or platinum regimen, febrile neutropenia is a major issue
that must be carefully managed, notably relying on GCSF (24)
or eventually with an antibiotic prophylaxis. Another challenge
is to keep a calories intake around 1500 kcal, as far as possible
using nutritional supplements or enteral nutrition with gastros-
tomy or jejunostomy (25). Onco-geriatric systematic evaluation
is another clue to decrease toxicity by managing age-related
fragility (26–28). We can also hypothesize that toxicity of RT will
decline in the next few years thanks to the technical progress
of RT as gating technique and new treatment planning tech-
niques as intensity-modulated radiotherapy including volumetric
modulated arc therapy (29–31).
In conclusion, our results suggest that a curative treatment
of OC based on RT is feasible on patient over 75 years, with an
acceptable tolerance. The outcome remains poor but consistent
with results in younger patients. With the use of a comprehensive
geriatric assessment, no treatment modification is needed what-
ever the age of patients. Surgical resection should be recommended
as the standard treatment for adenocarcinoma of lower esophagus
or gastroesophageal junction in elderly patients with good PS and
low co-morbidity profile, as it is in younger patients.
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Figure S1 | Overall survival curve using Kaplan–Meier methods for elderly
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